Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 5/20 | 1.00 |
| ▸ | DNMT3B | Q9UBC3 | 3/20 | 1.00 |
| ▸ | PNMT | P11086 | 2/20 | 1.00 |
| ▸ | DNMT1 | P26358 | 2/20 | 1.00 |
| ▸ | PRMT7 | Q9NVM4 | 2/20 | 0.88 |
| ▸ | AHCY | P23526 | 6/20 | 0.78 |
| ▸ | NADK | O95544 | 1/20 | 0.78 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.74 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.74 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.74 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.74 |
| ▸ | SUV39H1 | O43463 | 1/20 | 0.74 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.74 |
| ▸ | INMT | O95050 | 1/20 | 0.74 |
| ▸ | NSD2 | O96028 | 1/20 | 0.74 |
| ▸ | NNMT | P40261 | 1/20 | 0.74 |
| ▸ | HNMT | P50135 | 1/20 | 0.74 |
| ▸ | WDR5 | P61964 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8572440 | 1.00 | DOT1L (1.00) | DOT1LDNMT3BPNMTDNMT1PRMT7 | |
| SCHEMBL14174635 | 1.00 | DOT1L (1.00) | DOT1LDNMT3BPNMTDNMT1PRMT7 | |
| SCHEMBL16272276 | 1.00 | DOT1L (1.00) | DOT1LDNMT3BPNMTDNMT1PRMT7 | |
| SCHEMBL14158851 | 0.94 | DOT1L (1.00) | DOT1LDNMT3BPNMTDNMT1PRMT7 | |
| SCHEMBL1398379 | 0.94 | DOT1L (1.00) | DOT1LDNMT3BPNMTDNMT1PRMT7 | |
| SCHEMBL10665713 | 0.94 | DOT1L (1.00) | DOT1LDNMT3BPNMTDNMT1PRMT7 | |
| SCHEMBL14174636 | 0.94 | DOT1L (1.00) | DOT1LDNMT3BPNMTDNMT1PRMT7 | |
| SCHEMBL8943671 | 0.93 | DOT1L (0.86) | DOT1LDNMT3BPNMTDNMT1PRMT7 | |
| SCHEMBL8943656 | 0.93 | DOT1L (0.86) | DOT1LDNMT3BPNMTDNMT1PRMT7 | |
| SCHEMBL1490901 | 0.91 | DOT1L (0.84) | DOT1LDNMT3BPNMTDNMT1PRMT7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| EP-1844062-A2 | INHIBITORS OF DNA METHYLTRANSFERASE | Methylgene, Inc. (CA) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006078752-A2 | INHIBITORS OF DNA METHYLTRANSFERASE | METHYLGENE, INC. (CA) | 2006-07-27 | — | — | WO | disclosed |
| EP-1482977-A1 | COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS | PFIZER INC. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | AGOURON PHARMACEUTICALS INC. | 2004-03-04 | — | — | US | disclosed |
| WO-2003074083-A1 | COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS | PFIZER INC. (US) | 2003-09-12 | — | — | WO | disclosed |
| US-RE35904-E | COMPOUND CAPABLE OF BINDING TO ES NUCLEOSIDE TRANSPORTER OF ANIMAL CELLS | GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 1998-09-22 | — | — | US | disclosed |
| US-5236902-A | Method and probes for detecting nucleoside transporter and method for producing the probes | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 1993-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | DNMT3B, DNMT1, DNMT3L | DOT1L 24/4885DNMT3B 1/4885PNMT 154/4885 |
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | APRT, MTAP, TYMP | DOT1L 1250/4885DNMT3B 408/4885PNMT 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.